OTC:EVFM
Evofem Biosciences, Inc.
EVFM is a clinical-stage biotech firm utilizing proprietary platforms to develop novel treatments for female health conditions including endometriosis and oncology.
Key Metrics
Investment Thesis
Bull Case
EVFM offers exposure to the high-growth female health market through differentiated proprietary technologies that address unmet medical needs in endometriosis and oncology. If upcoming clinical trials succeed, the company could unlock significant value through product launches and potential licensing deals with major pharmaceutical partners.
Bear Case
The stock faces severe fundamental headwinds including a negative equity position of $66.5M, operating cash burn of $3.9M, and no current revenue from commercial products. Investors should be wary of the high risk of dilution from frequent capital raises needed to sustain operations against a backdrop of shrinking cash reserves.
About Evofem Biosciences, Inc.
EVFM (Evofem Biosciences) is a clinical-stage biopharmaceutical company focused on developing proprietary technologies for the female health sector, primarily serving the reproductive endocrinology and oncology markets. The company leverages its unique platform to create targeted therapies for conditions such as endometriosis and breast cancer. Key products are currently in advanced development stages pending regulatory approval and commercial launch.
Analysis
Management Discussion
Despite a 7.6% year-over-year revenue growth reaching $19.4M, the company continues to report substantial net losses of $8.9M driven by elevated general and administrative costs of $11.6M and marketing expenses of $9.2M. The balance sheet shows a significant retained earnings deficit of nearly $900M with current liabilities exceeding assets, indicating a heavy reliance on capital raises or cash reserves to fund ongoing clinical trials.
Industry Overview
The female health biotechnology sector is experiencing rapid expansion driven by increased awareness of women's specific medical conditions and growing demand for targeted therapies. This industry is characterized by high R&D costs, long development cycles, but also the potential for blockbuster treatments if clinical success is achieved.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $16.8M | $18.2M | $19.4M |
| Cost of Revenue | $4.4M | $6.5M | $3.8M |
| Gross Profit | $12.4M | $11.7M | $15.5M |
| Operating Expenses | $96.5M | $29.6M | $23.2M |
| Operating Income | $-84.1M | $-17.8M | $-7.7M |
| R&D | $25.0M | $2.9M | $1.8M |
| G&A | $27.6M | $14.9M | $11.6M |
| Marketing | $44.0M | $11.7M | $9.2M |
| Stock-Based Comp | $3.3M | $1.2M | $847.0K |
| D&A | $1.0M | $477.0K | — |
| Depreciation | — | — | $30.0K |
| Amortization | — | — | $619.0K |
| Other OpEx | $0 | $0 | $619.0K |
| Non-Operating Income | $7.5M | $70.8M | $-1.2M |
| Interest Expense | $2.2M | $2.3M | $2.2M |
| Interest Income | $85.0K | $31.0K | $16.0K |
| Pre-Tax Income | $-76.7M | $53.0M | $-8.9M |
| Income Tax | $44.0K | $17.0K | $0 |
| Continuing Ops | $-76.7M | $53.0M | $-8.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-76.7M | $53.0M | $-8.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-76.7M | $53.0M | $-8.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $12.7M | $9.2M | $13.6M |
| Cash & Equivalents | $2.8M | — | — |
| Accounts Receivable | $1.1M | $5.7M | $9.8M |
| Inventory | $5.4M | $1.7M | $1.6M |
| Prepaid Expenses | $2.2M | $1.2M | $1.5M |
| Other Current Assets | $1.2M | $580.0K | $741.0K |
| Long-Term Assets | $12.5M | $1.3M | $10.2M |
| PP&E (Net) | $3.9M | $1.2M | $458.0K |
| Operating Leases | $4.4M | $106.0K | $89.0K |
| Other LT Assets | $4.1M | $35.0K | $9.6M |
| Total Assets | $25.2M | $10.6M | $23.8M |
| Current Liabilities | $93.8M | $72.5M | $80.4M |
| Accounts Payable | $15.0M | $17.0M | $16.2M |
| Current Leases | $2.3M | $97.0K | $82.0K |
| Other Current Liab | $72.4M | $51.1M | $58.7M |
| Long-Term Liabilities | $3.1M | $8.0K | $9.8M |
| LT Operating Leases | $3.1M | $8.0K | $7.0K |
| Other LT Liab | $0 | $0 | $9.8M |
| Total Liabilities | $97.0M | $72.5M | $90.3M |
| Shareholders' Equity | $-71.8M | $-61.9M | $-66.5M |
| Paid-In Capital | — | $823.0M | $829.0M |
| Retained Earnings | $-938.7M | $-888.7M | $-897.7M |
| AOCI | $49.5M | $-849.0K | $-2.6M |
| Total L&E | $25.2M | $10.6M | $23.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-76.7M | $53.0M | $-8.9M |
| Non-Cash Adjustments | $17.9M | $-65.8M | $-10.4M |
| Working Capital Changes | $-11.6M | $3.9M | $15.4M |
| Cash from Operations | $-70.4M | $-9.0M | $-3.9M |
| Capital Expenditures | $341.0K | $4.0K | $14.0K |
| Cash from Investing | $-341.0K | $-4.0K | $-569.0K |
| Debt Issuances | $11.5M | $5.6M | — |
| Debt Repayments | $5.9M | $1.2M | — |
| Share Buybacks | $18.0K | — | — |
| Cash from Financing | $61.9M | $4.8M | $4.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-8.8M | $-4.2M | $161.0K |
| Beginning Cash | $13.6M | $4.8M | $580.0K |
| Ending Cash | $4.8M | $580.0K | $741.0K |
Frequently Asked Questions
How does Evofem Biosciences, Inc. make money?
Reproductive Endocrinology Therapeutics, Oncology Solutions, and Platform Technology Licensing
What are the main risks for EVFM?
Significant operating losses due to high research and development expenditures, reliance on external financing given negative shareholders equity and cash flow from operations, potential delays in regulatory approvals for new therapies, and intense competition within the female health biotech sector.
What is EVFM's competitive advantage?
Proprietary platform technologies enabling targeted drug delivery systems for female-specific health issues, strong intellectual property portfolio protecting core innovations, and strategic partnerships with leading biopharmaceutical entities to advance clinical pipelines.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.